CSIMarket Company Name, Ticker, Industry, else..
 
Dmk Pharmaceuticals Corporation  (NASDAQ: DMK)
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 7
 Employees -
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) 0

Business Description


DMK Pharmaceuticals Corporation is a multinational pharmaceutical company headquartered in New York, USA. The company specializes in the research, development, manufacturing, and distribution of various pharmaceutical products. Established in 1995, DMK Pharmaceuticals has a diverse range of medications in its portfolio, including prescription drugs, over-the-counter medicines, and generic pharmaceuticals. The company focuses on delivering high-quality and affordable healthcare solutions to improve patient outcomes. With a strong commitment to innovation and customer satisfaction, DMK Pharmaceuticals has become a trusted name in the pharmaceutical industry.


   Company Address: 11622 El Camino Real San Diego 92130 CA
   Company Phone Number: 997-2400   Stock Exchange / Ticker: NASDAQ DMK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -3.06%    
BMY   -0.7%    
JNJ   -2.63%    
LLY   -7.23%    
MRK   -1.92%    
PFE        1.75% 
• View Complete Report
   



Contract

DMK Pharmaceuticals Resurges with ZIMHI Rights and Seeks Lucrative Global Partnerships to Drive Revenue Growth

Published Thu, Dec 21 2023 1:15 PM UTC

DMK Pharmaceuticals Secures Full Rights to Commercialize ZIMHI and Seeks Lucrative PartnershipsIn a strategic move to expand revenue generation, DMK Pharmaceuticals has successfully regained full rights to commercialize their highly anticipated product, ZIMHI. This significant development allows the company to establish a stronger foothold in the pharmaceutical market and pu...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.5
Working Capital Ratio 0.59
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.68 $
Revenues (TTM) 0.5 $
Cash Flow (TTM) 0.6 $
Cash 0.94 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) 6.04
Asset Turnover Ratio (TTM) 0.42

Profitability Ratios Current
Gross Margin (MRQ) -3635.25 %
Operating Margin (MRQ) -36030.73 %
Net Margin (MRQ) -15317.21 %
Net Cash Flow Margin (MRQ) 66139.67 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.